Targeting BRAF in BRAF-mutant melanoma is highly effective, but most patients develop resistance. Heat shock protein 90 (HSP90) has been implicated and identified as a therapeutic target. Ultimately, early stage clinical investigation will be necessary to provide proof-of-principle of this approach, and if appropriate randomized trials to confirm promising findings.
https://ift.tt/2KSaFcf
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.